The Motley Fool

Profit From 2015’s Dividend Bonanza With GlaxoSmithKline plc, Royal Dutch Shell Plc, Persimmon plc And Neil Woodford

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

2015 is set to be a record year for UK dividends with data company, Markit forecasting an 11% year-on-year jump in the total value of dividends paid by UK companies to a total of £85.3bn.

And there are plenty of ways that you can get in on the action. 

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic… and with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. And if you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio.

Click here to claim your free copy now!

Special payout

Spearheading the surge in dividend payments is GlaxoSmithKline (LSE: GSK)

At present Glaxo offers a regular dividend of around 80p per share, a yield of 5.7%, an impressive figure that you’d be hard pressed to find elsewhere. The payout is currently covered one-and-a-half times by earnings. What’s more, this year the company is planning to return an additional £4bn to investors following its asset-swap with peer Novartis

With around 4.9bn shares in issue, a cash return of £4bn works out at around 82p per share as a special dividend, doubling Glaxo’s annual payout.

Actually, without this special payout the value of the estimated increase in ordinary dividends is 4.4%, so Glaxo alone is responsible for the majority of the increase in dividend payouts to investors this year. 

Persimmon (LSE: PSN) is also set to pay investors a hefty special dividend this year. As part of the company’s plan to return £1.9bn — £6.20 per share — to investors over several years, management is planning to pay a special dividend of 95p per share this year.

City analysts reckon that Persimmon’s dividend payouts will equate to a yield of 6.3% during 2015 and another special payout is planned every year until 2021. Specifically, Persimmon’s management is forecasting a special payout of at least 10p per share during 2016 and 2018 and payouts of 110p, 110p, 115p and 25p per share for the years 2017, 2019, 2020 and 2021. 

Under pressure 

Royal Dutch Shell (LSE: RDSB) is yet another dividend champion. City analysts believe that the company’s shares will support a dividend yield of 5.7% next year despite the falling oil price. Indeed, some analysts have begun to speculate that with the price of oil collapsing, oil giants like Shell will be forced to cut their dividends in order to save cash. But Shell is unlikely to cut its payout in the near-term. 

You see, Shell has a reputation to uphold. The company has paid a dividend to investors every year since the Second World War, a period which has seen a lot of volatility in the oil market and it’s unlikely to ruin this reputation now. Shell knows how to handle itself in a crisis and the company should be able to navigate through the current storm. 

Vodafone’s (LSE: VOD) dividend is also under pressure as the company is paying out more to investors than it is earning on a per-share basis. For example, City analysts expect the company to pay a dividend of 11.3p per share this year, although the same forecasts expect the company to only earn 6.2p per share for the period.

Still, for the time being most analysts believe that Vodafone’s dividend is safe and the company has plenty of cash on its balance sheet to fill the gap. 

Leave it to the experts 

Of course, if you don’t feel comfortable investing in a single company like Glaxo, Shell, Persimmon, or Vodafone you can buy a fund and Neil Woodford’s, CF Woodford Equity Income Fund is one of the best around.

The CF Woodford Equity Income Fund currently yields 4% and depending on which platform you buy through, the annual management charge is around 1%. 

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.